A Phase 2, Long-Term Extension (LTE) Study with Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus Who Have Completed the M19-130 Phase 2 Randomized Controlled Trial (RCT)
Details
Age
Adult
Type of Study
Treatment
Locations
Barbara Davis Center
University of Colorado Hospital
Principal Investigator
Christopher Striebich, MD, PhD
Study ID
Protocol Number: 22-0815
More information available at ClinicalTrials.gov: NCT04451772
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers